Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) has reported a loss for its second fiscal quarter (ending June 30) of $-1.52 versus a loss $-2.25 for the same period a year ago. For the latest four quarters through June 30, E.P.S. were $-7.29 versus $-10.24 for the same period a year ago.
Recent Price Action
Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) stock declined modestly by -1.9% on 8/1/24. The stock closed at $44.15. This decline was accompanied by normal trading volume. The stock has performed in line with the market over the last nine months and has declined -2.1% during the last week.
Current PriceTarget Research Rating
RARE is expected to be a modest Value Builder reflecting capital returns that are forecasted to be above the cost of capital.
Ultragenyx Pharmaceutical has a current Value Trend Rating of F (Lowest Rating). The Value Trend Rating reflects consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Ultragenyx Pharmaceutical has a poor Power Rating of 28 and a very low Appreciation Score of 3, triggering the Lowest Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment